Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Department of Health and Human Services National Institutes of Health
Posted on

Application Deadline

Type

Research/project funding

Reference Number

PAR-22-047

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Categories: Health.

More Information

Visit Website

Posted on

Application Deadline

Type

Research/project funding

Reference Number

PAR-22-047

United States